Source: International Congress 2018 – Drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Starshinova (St.-Peterburg, Russian Federation), M. Filatov (St.-Peterburg, Russian Federation), M. Nazarenko (St.-Peterburg, Russian Federation), V. Burdakov (St.-Peterburg, Russian Federation), S. Landa (St.-Peterburg, Russian Federation), E. Istomina (St.-Peterburg, Russian Federation), G. Marfina (St.-Peterburg, Russian Federation), P. Yablonskiy (St.-Peterburg, Russian Federation). The first experience of therapeutic dendritic cells vaccine administration in patients with extensively drug resistant lung tuberculosis. 3682

Member's Comments

No comment yet.

Related content which might interest you: The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 Diaskintest at patients after successful treatment of lung tuberculosis Source: International Congress 2017 – Migrants and screening Year: 2017 Method of treatment of destructive tuberculosis of single lung with extensively drug resistant mycobacteria tuberculosis Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions Year: 2011 The clinical characteristics and treatment responses of tuberculosis in patients with malignancy on anti-cancer chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005 TB infection in children receiving genetically engineered biologic drugs Source: International Congress 2019 – Paediatric tuberculosis Year: 2019 Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 Chemotherapy efficacy in TB patients resistant to major and reserve drugs Source: Eur Respir J 2005; 26: Suppl. 49, 648s Year: 2005 Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007 Clinical efficacy of once a day linezolid and azithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 The experience of additional treatment of MDR-TB patients using autologous mesenchymal stem cells Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Adjuvant therapy with autologus mesenchymal stem cells in extensively drug-resistant pulmonary tuberculosis. A case study Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis Source: Eur Respir J, 50 (5) 1701552; 10.1183/13993003.01552-2017 Year: 2017 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Treatment results in patients with drug resistant pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 612s Year: 2002 A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis Source: Eur Respir J, 51 (2) 1702166; 10.1183/13993003.02166-2017 Year: 2018 Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003 Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019